VIDAPAL – Antivirus Antigens

Author: _AdM#FDCA_ on 26-03-2019, 16:03, Views: 4908

VIDAPAL – Antivirus Antigens

VIDAPAL – Antivirus Antigens

Description:

Nutritional Beverage extracted from Cactus leaves & Guava fruit, HIV – vaccines extracted from Cactus leaves, Antivirus Antigens extracted from Cactus leaves to treat AIDS, HIV +, Hepatitis – C and Influenza.


Country:
Mexico (Beneficiaries States: Zacatecas, Aguascalientes, San Luis Potosi)

People Benefiting: Direct: 50 employees at the plant | Indirect: 1,000 community workers (non-employees)

Amount Required: USD$ 3,000,000.00


VIDAPAL – ANTIVIRUS ANTIGENS – EXECUTIVE SUMMARY


INDUSTRIALIZADORA Y COMERCIALIZADORA DE LAS CACTACEAS, SA de CV (ICC) and SIETE have performed several studies and analysis to produce food and biochemical organic and non-organic products to improve health of human beings as well as contributing to the rural areas development and promotion of its products. With this main goal, ICC has established the production facilities in the State of Aguascalientes, Mexico, within over a half million sq. feet land, which has a construction area for production, shipping, warehouse and service areas with over 314,000 sq. feet. In addition, there is another area across the road for trailer weighting with about 187,000 sq. feet that also is used for ICC shipping services.

The Laboratory area in San Luis Potosi has over 5,000 sq feet for laboratory and research activities mainly in the biological and nutritional fields, plus another administrative building and over 100,000 sq feet for production, plus shipping yards for truck loading.

The main product that has been considered, is an exotic beverage call Nopal-Guayaba (Cactus leaves and Guava fruit, with no preservatives, no sugar, sweetened with Fructose) that can also be enriched with cholesterol reducing agents or glucose reducing agents. In the social side, this business also allow to increase the labour in rural areas, by subcontracting non formal agricultural labour, and hiring them to cut the cactus leaves needed as main row material for Opuntia products, this is the main reason to have the full support of the Governor of Aguascalientes, for which tax benefits have been approved. The cactus plants can be either grown in private areas, but also it can be found in desert areas that are not privately owned, so the cost for the plant is reduced while we help by providing additional source of revenue to very low income people that does not own even a piece of land.

The great advantage of these products and the related patents and secret formulas, is that the production facilities can be also located in areas where the required types of cactus leaves are grown (Europe, desert areas of Asia, South America, etc.). Just Mexico produce over 1 million tons of this type of cactus (about half million man helped grown) and half grows wild in desert type areas. Out of the 158 different varieties of cactus plants that are grown in Mexico (either in nurseries and wild grown), only 8 of them have special scents and characteristics that make them suitable for the production of unique substances with molecular compositions that has special properties that make them suitable to strengthen the human immune system.

The main projects that are now being implemented, after years of study and corporate restructuring, the group of companies have continued the production, in a limited capacity, of some products that will help the human being to improve health conditions, with products like antivirus antigens, 100% natural vitamin C, 100% purity fructose, cholesterol and glucose reducing pills, most of them from cactus plants.

Also, there is a process that has not been patented, but high purity (99.93%) fructose can be obtained from regular corn fructose (about 53% fructose and 45% dextrose and sucrose, bacterial free). This process would not only let us reduce and control direct cost for sweeteners for the beverages, but also to create a spin-off company to product fructose based IV, that has great potential for diabetic people.
The plant is located in the Tepezalá county in Aguascalientes State, in the middle of the Mexican Republic.

VIDAPAL – Antivirus Antigens


The exact location of the plant and the R&D Lab is shown in the following map. The distance between the two facilities is about 2 hours’ drive. R&D activities are primarily done in an isolated and aseptic environment, and production has mainly the objective to handle high volume of products.

VIDAPAL – Antivirus Antigens

VIDAPAL – Antivirus Antigens

VIDAPAL – Antivirus Antigens

VIDAPAL – Antivirus Antigens

VIDAPAL – Antivirus Antigens


The industrial activities are supported by the Group’s R&D laboratory located in the city of San Luis Potosi, about 130 miles from the Aguascalientes plant. The Laboratory is called SIETE (Servicios de Investigación y Estudios Técnicos Especializados, SA de CV).
With the R&D activities, several patents and proprietary formulas were developed, including:
Process to obtain natural oil from Cactus fruit seeds (Tuna fruit).
Process to obtain Alpha-Cellulose from the Cactus fruit skin and cactus leaves.
Process for the stabilization and bottling of cactus and fruit based nectar.
Process for the stabilization of an alcoholic and cactus fruit beverage.
Process for the stabilization and bottling of Cactus and Guava juice, enriched with fructose and cero preservatives.
Process to obtain vitamin C from Guava.
Process for the stabilization and preservation of cactus fruit juice.
Process for the crystallization of the highest purity fructose from cactus fruit for beverage and medical use.
Process to obtain antivirus antigens and cholesterol and glucose reducing scents.

SIETE R&D LAB IN SAN LUIS POTOSI


VIDAPAL – Antivirus Antigens
VIDAPAL – Antivirus Antigens
VIDAPAL – Antivirus Antigens
VIDAPAL – Antivirus Antigens
VIDAPAL – Antivirus Antigens


There were other R&D activities performed that allow the Opuntia related scientist to obtain medical products like the vitamin C from Guava (Ascorbic Acid) as mentioned above, as well as others that can benefit the human body, like Cholesterol reducing and glucose reducing formulas from Cactus, also both processes patented and up to early stages, the isolation of an virus antigen from Cactus that has huge potential to treat virus threats with success stories in the most important hospitals in Mexico, but this still has to be continued in its development. Also, with the fructose crystallization patented process of the highest purity, it can also be used to produce fructose based IV instead of the glucose based IV. This application could benefit patients with Diabetes Mellitus Type II, which has spread significantly all over the world, mostly in developed countries.

The production of the Cactus-Guava beverage requires of important quantity of row materials, at least 150 grams of cactus and 150 grams of guava (or other fruits) per litter of juice. The collection process, delivery at the plant and part of the process will generate hundreds of both direct and indirect jobs, for people living in the country side that not even require for them to own a piece of land to grow the cactus, while this can be found wild grown in most of the semi desert areas of the countries located above or close the Cancer or close-below Capricorn tropics.

All these products require approximately 100,000 tons of cactus leaves per year, out of which, 60% will come from deserted areas where wild cactus grow. This requirement will allow to give job opportunities to people who live in the desert areas of Mexico, close to the manufacturing plants, who can harvest between 50 to 100 kilos of cactus per day, so about 1,000 families will be indirectly beneficiated with indirect jobs in areas where there are no job opportunities. The deserted areas close to the production facility, are in the state of Zacatecas, Aguascalientes and San Luis Potosi. Our plan will need to get from the Local and Federal Government to implement collection centers to then carry the cactus to the plant for cleaning and process. The production process will generate approximately 50 direct jobs on the plant.


A NEW APPROACH TO AN HIV-VACCINE:

VACCINES AGAINST HIV: HOPE AND REALITY


It was about 20 years ago when the virus which induces AIDS, the Acquired Immune Deficiency Syndrome, has been first identified. It was called HIV for Human Immunodeficiency Virus. Initially, researchers believed that a protection against the virus by means of an effective vaccine was just a few years away.
Vaccination had been extremely successful with other relatively simply viruses, such as polio. It was developed at a time when all the tools of modem generic engineering and protein chemistry were not yet available. This gave rise to hope. Especially, since HIV is one of the most simple organisms. This is a far cry away from much more complex bacteria such as tuberculosis or parasites such as those inducing malaria.

However, the initial optimism was fading quickly. It was discovered that HIV is a retrovirus, i.e. type of infectious agent which was considered impossibly to exist in nature even a few years before the first AIDS cases were discovered. There is only one other retrovirus occurring in humans. However, it is much less infectious and less dangerous than HIV. Retroviruses have the unique capability of REPLACEing their whole genetic information into the genome of the cell. In other words, the virus becomes an indistinguishable part of the genetic information of a human being which has been infected. Each time an infected cell replicates itself, the genetic information of the viruses is passed along as well.
Thus, HIV is not a parasite which can be cleared from the body - it becomes an integral part of the body soon after the infection. Once this has occurred, a few hours after infection, it is virtually impossible to get rid of the virus ever again.

Accordingly, the task of vaccine development for HIV is much harder than that of any other vaccine. An HIV-vaccine must prevent that any cell becomes infected. Other vaccines are just priming the immune system of the body so that it "knows" about the infectious agent before the actual infection occurs. This "knowledge" enables the already formed immune cells to recognize the infectious agent. Subsequently, they replicate quickly and produce antibodies or killer cells. Thus, the spread of the infection in the body can be curtailed before it can do any significant harm. In other words, the current vaccines do not prevent the infection, they just facilitate the response to an infection to such an extent that the infection is kept from causing disease. Also, the infectious agent is usually cleared from the body completely. An HIV-vaccine has a much harder, almost impossible task: ideally it must prevent that even a single cell is infected.

The most effective vaccine concept so far has been to weaken (attenuate) an infectious agent so that it cannot cause disease but elicits to strongest possible response of the immune system. This is not applicable for an HIV vaccine, although attenuated HIV versions have been created by genetic engineering. They reason is that the virus can only replicate if h retains its capability to REPLACE its genes into the human genome. In other words, an attenuated HIV-vaccine would still cause the dangerous modification of genome of the infected cells, giving rise to rare forms of cancer and potentially new forms of disease. This is too much of risk.

The next choice was to use those outer proteins of HIV which are responsible for the highly specific "docking mechanism" by which HIV recognizes its targets cells, predominantly the so-called CD4-positive cells. The goal was to induce neutralizing antibodies, i.e. antibodies which block the ability of HIV to infect its target cells. However, HIV has protected itself against such antibodies by surrounding the docking protein (gp120) with a big larger of sugar-derivatives. The most important and unprotected part of gp120 is called the V-3 loop. Unfortunately, it is quite variable in its structure. Neutralizing antibodies will recognize this "docking site" only if they are directed exactly against the strain of HIV which causes the infection.

This is quite unlikely, given the large number of different HIV-strains and the added variability of the "docking site" of HIV even within one HIV-strain.
Despite of these theoretical difficulties, some studies were made with vaccines which were capable to elicit neutralizing antibodies against at least some variants of the HIV-"docking sites". Unfortunately, recent results of a field study in Africa have demonstrated the failure of this approach.

More sophisticated ways of presenting parts of HIV to the immune system have to take this lesson into account. For example, the genetic information encoding important parts of HIV can be injected into the muscle if it is packaged as part of a so-called "expression plasmid". In this context, the cells produce HIV-proteins although no infectious virus develops.

In extension of this concept, certain HIV-genes have been REPLACEed into so called "recombinant vectors", i.e. live viruses or bacteria which do not cause disease. If certain HIV genes are REPLACEed into their genetic information, these vector organisms produce the corresponding HIV-proteins in the course of infection. Many different versions of such vector-constructs are currently under evaluation but large scale clinical studies have not even been started.

Nevertheless, this approach appears to be the most promising because it can elicit not just the production of neutralizing antibodies against HIV, it can also induce the generation of the very important cytotoxic T-cells which can kill cells already infected by HIV. The combination of such antibodies and killer cells may actually master the apparently impossible task of preventing any HIV-infected cell, provided a cocktail of such vectors is used which represent most or even all of the many different HIV-strains and variants. Otherwise, such vaccines will protect only against one strain of HIV while leaving people unprotected against others.

Finally, the difficult ethical and practical questions regarding the evaluation of the efficiency of a potential HIV-vaccine should be mentioned. Participants in such studies will usually appear HIV-positive in most HIV-assays, thus causing significant fear of stigmatization, especially in developing countries.

Furthermore, ethical considerations demand that participants in vaccine studies must be comprehensively informed about HIV and efficient measures to protect themselves from infection. Studies have shown that such information is dramatically reducing the risk behaviour of participants as proper counselling and testing documents.

Obviously, this poses another ethical problem similar to that occurring in trials with cancer drugs. Even a study design as proposed above has been put into reality, it will take at least 5 years of observation of these 20,000 individuals until reliable data can be expected.

Compared to the size of academic and industrial research dedicated to the development of new anti-HIV drugs and the understanding of the basic science behind potential new drug targets, the research dedicated to HIV vaccines has been marginal during the last 20 years. Therefore, an imitational HIV vaccine ºinitiative has been crated and is partially funded by philanthropic sources. Only a few of the big pharmaceutical companies have made a serious effort toward HIV vaccine development.

The man reason for this discrepancy is the lack of sufficient commercial prospects. The massive decline of new HIV-infections in the developed countries has lowered the interest in an HIV-vaccine. As it is the case with drugs for the diseases which are prevalent in developing countries, the big companies do not see that sufficient funds will become available to create a commercially viable market for HIV vaccines in the developing countries.
There are essentially two responses which an effective anti-HIV vaccine must elicit:

a) The first one is the generation of so-called "neutralizing" antibodies, i.e. antibodies which bind to HIV in such a way that the virus cannot bind to its receptor CD4 and/or cannot fuse with the target cell after the binding has occurred.

b) The second one is the generation of so-called "cytotoxic T-cells" which are capable of recognizing HIV-infected cells and destroy them. This is achieved by the T-cell receptors al the surface of such cells which recognize (in a manner similar to that of antibodies) certain parts of HIV, thus making their "killer effects" highly selective towards HIV-infected cells and not to the normal cells. Obviously, the latter activity is best suited for therapeutic vaccination, i.e. an approach to strengthen the immune system in a specific way which enhances its capacity to key the HIV-production at a low level once the infection has occurred and established itself within the body. They effect of a therapeutic vaccine would be merely to keep and HIV-infection from progression to the AIDS stage. Since HIV can hide itself by REPLACEing its genome into cells which do not produce virus (i.e. cannot be recognized by the specific killer cells), it may not be possible to eradicate HIV completely by therapeutic vaccination.

Focusing upon a), i.e. the generation of neutralizing antibodies, there is only one target left: the V3 loop. As discussed above, the V3 loop has an essential function during the fusion of the virus with the infected cell, however it is quite variable and different types of V3 loops are found in different HIV-strain.

As shown in the picture below, the V3 loop is part of a group of peptide loops which are located outside the protective glycan shield which shields the HIV gp120 protein against antibodies. Therefore, a combination of V3 loops from different HIV-strains with other outer peptide loops of gp120 could be a good vaccine candidate.

VIDAPAL – Antivirus Antigens


We have cloned, expressed, purified and characterized such proteins, including the so-called gp120-BEDO (see also gp120 AVC-H1-antigen table above).

Using hundreds of different sera from HIV-patients from Mexico and Cuba, we could show that the antigens at this protein are recognized by the large majority of the patient sera. This is noteworthy since the protein was attached to the detection membrane, thus presenting only a fraction of its potential recognition sites to the antibodies. It is therefore likely that the recognition will be close to 100% if the BEDO protein is used as main vehicle of the AVC-H1 antigen.

Accordingly, the BEDO is a very good proof of principle and may well be suited to be used in initial treatment or as vaccine studies in humans. Of course, future refinement of this approach by creating a variety of different BEDO proteins (as it has been done with the AVC-H1-protein shown in the tables above) will be desirable to optimize the structure of this potential reacting antigen protein and or to combine it with other, similar proteins.


ANTIVIRUS ANTIGENS


It would be very risky to say that we have identified and isolated an antivirus antigen that has cured some mortal diseases, but what we can say is that we have had the opportunity to isolate and extract an antigen that has a protein with the same molecular weight and very similar composition of the protein that you can find in the Human Immune System cells, and we have it tested in patients with different diseases, including influenza and even HIV+/AIDS, where has shown better response in patients in early stages of the disease (about 70%) than those in the more advance stages (almost no reaction at all). Those tests were performed at the IMSS La Raza central hospital in Mexico City.


Note: it is important to say that new research protocol has been started to determine if such new antigen has been adequately structured, while it is our believe that with a more precise electromagnetic fields, source and exposure of the final antigen cells, free electrons shall facilitate the docking of t-cells protein and neutralize aids cells. The results of this new protocol were finished in early 2007, with a tentative infected target of 25 people.


In the VIDAPAL, the antivirus Antigen that has been under test for over 15 years, the latest test protocol with humans was performed about one year ago and I will send you the positive results, as the product helps to reduce the viral count (is not a cure for AIDS), but by reducing viral count, quality of life in patients with +HIV, Hepatitis-C and other viral deceases. Also, metabolization (can be easily metabolized) and showed no side effects in Toxicity, Cancerigenicity tests. Also Genotoxicity alive were performed showing no side effects in pregnancy.

The main goal in that test protocol was to try Vidapal as the only treatment in patients with AIDS, HIV+, Hepatitis-C and Influenza. The results were very positive, by showing that the viral count in those patients (mainly in the ones which their illness was in the early stages) was reduced, giving the positive result of increasing their quality of life.

In patients with Hepatitis C, where only 1 patient shown great advance and health improvement, so we now consider him cured, but others, we could improve their health conditions significantly, to almost have normal life style. In addition, an executive male from a Mexican Nationwide TV broadcaster acquired Hepatitis C in a blood transfusion after a car accident, has been under treatment for over two years. The first 6 months was the stabilization with large doses (4 to 6 pills per day) for 6 months, and now is only under a maintenance treatment with one to two pills per day, with very good quality of life and low viral count.

This antivirus Antigen has been also tested in Cuba, in the Central Hospital of La Habana, where based in the information reported to us, they performed the protocol in 30 AIDS+ individuals in early stages, where 70% of them reported bacteria count reduced to less than 1% of what they were reporting before treatment and were considered as HIV+ with virus inert. The other 30% improved their life style to normal condition; therefore we consider that they were in more advanced stage of the disease. Neither official paperwork nor report was sent back to us, but the head doctor has volunteered to witness and sign any report if needed.

Recently, in order to continue the protocol and as a prerequisite stated by the Hospitals and AIDS treated patients, who wanted to have the product registered at the Mexican Secretary of Health (SSA), we decided to register the cactus fiber as a nutritional supplement that provides help to stomach digestion problems, so we called it Fiber of Nopal or VIDAPAL, while in order to obtain the registration as Medicine or even more, as an Antigen, we shall demonstrate its method of work, efficiency and results obtained, and this process will take several months even years, so we decided to start the registration and patent process as “Nutritional Supplement” that will allow us to continue with research protocols and commercialization of the product.

The experimental protocol performed with potential universe of patients included:

TOXICOLOGY STUDY
1. Toxicological study:
a. Study of growing doses up to 1,000 times the recommended doses.
b. Study to determine the recommended doses in 5 different animal species.
c. Study of allergy in Humans.
d. Embryo-toxicity study

2. Pharmacokinetic study

3. Pharmacodynamia study

4. Molecular study

5. Follow up study (see form EXSIDA AAC-01-S1)
a. Follow up to those patients that have been diagnosed and treated with AAC-01 nutracptic (antivirus antigen) for 6 months with total isolation, forming 3 groups, two groups that were treated with different doses and the third group as witness treated with placebo, all of them monitored with the following tests:
i. Blood test (emetic biometry)
ii. CD4 levels study (cooperative T-lymphocytes)
iii. Viral load test (PCR real time monitoring).


Form EXSIDA AAC-01-S1


As stated above, IT IS IMPORTANT TO SAY that we have started two new test protocols with these two categories of patients, individuals that have been identified with HIV+ and AIDS+ (about 100 patients, 80% in early stages, 10% in middle and 10% in advance stages), but only 29 of them were reported and controlled with the EXSIDA follow up form and studies.
The first case that was reported as successful is:

DSL, a heterosexual male of 34 years old (tested in April 1988), who was born in Zacatecas, Mexico, weight 148 lb, height 5’6”. He showed tiredness and Kaposi sarcoma in neck and two small in his back. He went to the National Nutrition central hospital and was diagnosed AIDS positive after three AIDS ELISA tests showing viral count of 73,000 vir/ml sera, losing 20 lb in the last two months. He was first treated with AAC-01 with no success after two months, so his viral count remains the same. The treatment was changed to AAC-02 (antigen with higher exposure to electromagnetic fields and more enzyme and protein concentration. With AAC-02 he showed great improvement after two months having 2 pills in the morning and 2 in the evening. After three months and in the final viral count analysis in Sept. 88, his weight increased to 165 lb and showing viral count to NON Detectable. This test was repeated 4 times with ELISA method to ensure results and in three different institutions and equipments. This is the first successful case for our antigen. This patient still continues having one pill per week as maintenance.

LIZ, a homosexual 26 years old male who was born in Matanzas, Cuba, weight 150 lb, height 5’8”, final testing in April, 2002, who at the beginning of the test presented hairy leucoplast in tongue, obtained by oral sex with other homosexual male. He was monitored in its early stages of the disease showing viral count of 10,000 virus per ml sera, diagnosed positive AIDS with ELISA test performed twice. His treatment was started with 3 AAC-01 per day in the first month, and then reduced to 2 pills per day from the second month completed acyclovir (swallowed). After 6 months no viral count was detected. He continues having one two pills per week as maintenance and practicing safe sex. (His report is included as attachment to this document).


ANTIVIRUS ANTIGEN FROM CACTUS


Once the antivirus antigen has been extracted from cactus leaves (Nopal and other cactus variants), non-infected HIV blood serum sample is added, to valuate its activity under the “sandwich” ELISA technique, in which antibodies against P24 are added at the bottom of a vase with a microplate or over polystyrene particles.

To the microplate vase with capture HIV antibodies, the serum with cactus antigen is added, and after a “washing” process HIV rabbit antibodies (detection antibodies) are added, and to the new mix serum formed, goat antibodies are added (marked) with specific against rabbit antibodies. Goat antibodies are joined with a degradated enzyme with specific substrate giving a yellow tone which intensity is proportional to the cactus antigen concentration. By using photometric measurement of the intensity of the color in the vase, the quantity of the amount of antigen is determined.
Concentration of active cactus antigen, are in the range of 7 to 10 picograms/milliliter. With this new substance, pills of cactus fiber with antigen level I can be prepared.

For level II antivirus antigen composition, the procedure is to prepare a sample with human blood serum non HIV infected, with cellular surface marker CD4. CD4 cells react with class II antigens of the main complex of hystocompatibility, liberating cytocines that activate and increase immunology response.
We consider that with this new generation of so-called "cytotoxic T-cells" which are capable of recognizing HIV-infected cells and destroy them. This is achieved by the T-cell receptors al the surface of such cells which recognize certain parts of HIV, thus making their "killer effects" highly selective towards HIV-infected cells and not to the normal cells. This theory is being detailed below in this document.

Obviously, the latter activity is best suited for therapeutic vaccination, i.e. an approach to strengthen the immune system in a specific way which enhances its capacity to key the HIV-production at a low level once the infection has occurred and established itself within the body. They effect of a therapeutic vaccine would be merely to keep and HIV-infection from progression to the AIDS stage. It is important to say that although we do not certify or pretend to be a cure for HIV/AIDS, our natural antigen can improve patient’s quality of life.

CD4 lymphocytes are the primary targets of HIV infection and the primary union place of HIV-1 is the CD4 receptor. Along the HIV-1 infection gets chronic, the CD4 lymphocytes is reduced significantly, and the loss of these cells is associated with new evolving opportunistic infections and maligned illnesses typically linked with AIDS.

Valoration of Cactus antigen level II is performed by retrospective process, which means, by the determination of free CD4 non captures by the antigen; this determination is done by the use of specific monocloned antibodies targeting the cell glucoprotein surface.

These are some of the results obtained along the 18 years the antigen has been tested with AIDS patients, some of those we have not been able to find them, but some other can witness the results achieved in their health conditions improvement. The lines highlighted, show the patients that achieved successful results by reducing their viral count to undetectable levels, leaving its immune system as an inert HIV+ without possibility to spread the illness and strengthening is immune apparatus to continue fighting the virus.


FINANCIAL HIGHLIGHTS


In the first phase, this project requires ballpark investment of $3 million USD to get to 200,000 pills per month production, which requires about 3 tons of cactus processing as raw material mainly. This investment will be used for equipment purchase from raw material prep. Through packaging, production site preparation, G&A for at least 6 months and raw material financing for rolling budget purchase for 6 months and marketing in Mexico. The EBITDA projected reaches 29% including marketing and after interests and taxes reaches 18%, so the loan-investment can be paid back in approximately 2 years.

VIDAPAL – Antivirus Antigens
VIDAPAL – Antivirus Antigens
VIDAPAL – Antivirus Antigens


PROCESS – PROCESS DIAGRAM


VIDAPAL – Antivirus Antigens


PRODUCTION AREA


How can the immune system be manipulated so that it will treat an antigen protein as if this would be a life virus?

The strength of an immune response against HIV must be much higher than that required for a successful vaccine against other infectious agents. Therefore, the limited attention which a "foreign" protein is mostly using getting by the immune system will not suffice.

However, this would be a different issue if the vaccine would elicit a local inflammation of the point of injection, similar to what occurs after the infection of life attenuated vaccines. The best case would be activation of local connective tissue mast cells. The mast cells are those cells which elicit inflammation and allergic reactions. They contain a cocktail of signal molecules in little vacuoles inside the cell which can be released within seconds after stimulation of the mast cells. In addition, enzymes in the membrane of the mast cells produce at the same time very powerful substances (called leukotrienes) which have Chemotactic properties. This means that the act already at very low concentrations and attract certain immune cells to migrate towards the point where the highest concentration of these factors can be found.

This is the same mechanism which attracts immune cells to the side of an injury in order to fight bacterial infiltration. Therefore, we are dealing here with a very reliable mechanism which has been developed in millions of years of evolution and has become essential for the survival of all higher animals.

We have previously cloned, developed, purified and characterized (not shown) various fusion proteins which use the constant part of the antibody which the mast cells use as their recognition sites: the IgE molecule. We found that the receptor part of the IgE molecule, the so-called Ec-part can be fused by molecular biology methods to recognition sites which interact with such molecule as the above mentioned BEDO-protein, a potential new product or pill that is loaded with our AVC-H1 antigen that has shown great reaction to attract HIV active cells and make them inert.

HEPATITIS C

There has been some tests reducing the ionization process and reducing the amount of active ingredient but expanding the critical mass of the antigen, so it has been tried in patients with Hepaitis C.

The test protocol executed in 1996 has to be performed again based in the fact that only two patients in Cuba and one in Mexico showed positive results by improving their health conditions, although only one showed much better and positive result than when he was treated with y-interferon. We are trying to determine the more precise efficiency of this antigen focusing the H-C Virus behavior.

We have been invited to participate in a new protocol in Mexico to identify first Hepatitis C contagioused people with a nationwide survey conducted by the Mexican Ministry of Health; we are promoting to select some people to be treated with our Antivirus Antigen.

On the other hand, we have been approached by Tasly, one of the largest supplement producers in China who has tested our product with very positive results. Other companies like Guangzeng Group in China (Pharmaceutical Distribution Company) and others in India, Oman, Chile, and USA have shown interest in distributing our Cactus based Antivirus Antigen.

Category: FEDUCA Projects » Vidapal – Antivirus Antigens

Dear visitor, you are browsing our website as Guest.
We strongly recommend you to register and login to view hidden contents.
Information
Would you like to leave your comment? Please Login to your account to leave comments. Don't have an account? You can create a free account now.